Milestone Scientific (MLSS) 10-Q 14 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Nov. 14, 2023
Document Information [Line Items]
Entity Central Index Key	0000855683
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-14053
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3545623
Entity Address, Address Line One	425 Eagle Rock Avenue Suite 403
Entity Address, City or Town	Roseland
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07068
City Area Code	973
Local Phone Number	535-2717
Title of 12(b) Security	Common Stock, par value $.001 per share
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		71,048,241
No Trading Symbol Flag	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,170,593	$ 8,715,279
Marketable securities	2,450,470	0
Accounts receivable, net	591,012	693,717
Prepaid expenses and other current assets	578,753	443,872
Inventories	2,482,630	1,792,335
Advances on contracts	1,699,153	1,325,301
Total current assets	9,972,611	12,970,504
Furniture, fixtures and equipment, net	9,182	18,146
Intangibles, net	188,314	227,956
Right of use assets finance lease	11,159	17,645
Right of use assets operating lease	378,142	443,685
Other assets	24,150	24,150
Total assets	10,583,558	13,702,086
Current liabilities:
Accrued expenses and other payables	1,111,742	1,124,839
Accrued expenses, related party	270,836	167,549
Current portion of finance lease liabilities	10,031	9,365
Current portion of operating lease liabilities	100,327	91,701
Total current liabilities	3,278,840	3,299,675
Non-current portion of finance lease liabilities	3,088	10,698
Non-current portion of operating lease liabilities	308,605	385,279
Total liabilities	3,590,533	3,695,652
Commitments
Stockholders’ equity
Common stock, par value $.001;authorized 100,000,000 shares; 70,893,748 shares issued and 70,860,415 shares outstanding as of September 30, 2023; shares; 69,306,497 shares issued and 69,273,164 shares outstanding as of December 31, 2022	70,894	69,306
Additional paid in capital	129,487,592	127,478,325
Accumulated deficit	(121,400,682)	(116,410,405)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific, Inc. stockholders' equity	7,246,288	10,225,710
Noncontrolling interest	(253,263)	(219,276)
Total stockholders’ equity	6,993,025	10,006,434
Total liabilities and stockholders’ equity	10,583,558	13,702,086
Nonrelated Party [Member]
Current liabilities:
Accounts payable	1,149,267	1,102,729
Related Party [Member]
Current liabilities:
Accounts payable	$ 636,637	$ 803,492

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	70,893,748	69,306,497
Common stock, shares outstanding (in shares)	70,860,415	69,273,164
Treasury stock, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product sales, net	$ 2,059,284	$ 2,215,699	$ 7,566,848	$ 6,564,969
Cost of products sold	555,850	762,964	2,284,730	2,749,160
Gross profit	1,503,434	1,452,735	5,282,118	3,815,809
Selling, general and administrative expenses	2,823,765	3,283,378	9,834,781	9,681,326
Research and development expenses	170,478	166,191	524,472	897,218
Depreciation and amortization expense	15,896	16,661	49,798	50,121
Total operating expenses	3,010,139	3,466,230	10,409,051	10,628,665
Loss from operations	(1,506,705)	(2,013,495)	(5,126,933)	(6,812,856)
Interest income	30,600	28,012	102,669	26,819
Loss before provision for income taxes	(1,476,105)	(1,985,483)	(5,024,264)	(6,786,037)
Provision for income taxes	0	0	0	0
Net loss	(1,476,105)	(1,985,483)	(5,024,264)	(6,786,037)
Net loss attributable to noncontrolling interests	(9,811)	(13,680)	(33,987)	(54,030)
Net loss attributable to Milestone Scientific Inc.	$ (1,466,294)	$ (1,971,803)	$ (4,990,277)	$ (6,732,007)
Net loss per share applicable to common stockholders—
Basic and Diluted (in dollars per share)	$ (0.02)	$ (0.03)	$ (0.07)	$ (0.1)
Weighted average shares outstanding and to be issued—
Basic and Diluted (in shares)	73,730,921	70,975,420	72,374,693	70,480,706

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Board of Directors [Member] Common Stock [Member]	Board of Directors [Member] Additional Paid-in Capital [Member]	Board of Directors [Member] Retained Earnings [Member]	Board of Directors [Member] Noncontrolling Interest [Member]	Board of Directors [Member] Treasury Stock, Common [Member]	Board of Directors [Member]	Consultant [Member] Common Stock [Member]	Consultant [Member] Additional Paid-in Capital [Member]	Consultant [Member] Retained Earnings [Member]	Consultant [Member] Noncontrolling Interest [Member]	Consultant [Member] Treasury Stock, Common [Member]	Consultant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Dec. 31, 2021													68,153,336
Balance at Dec. 31, 2021													$ 68,153	$ 124,915,560	$ (107,704,274)	$ (152,541)	$ (911,516)	$ 16,215,382
Stock based compensation														305,370	0	0		305,370
Common stock to be issued to employees for bonuses														164,385				164,385
Net loss															(1,901,723)	(17,502)		(1,919,225)
Net loss															(1,901,723)	(17,502)		(1,919,225)
Balance (in shares) at Mar. 31, 2022													68,153,336
Balance at Mar. 31, 2022													$ 68,153	125,385,315	(109,605,997)	(170,043)	(911,516)	14,765,912
Balance (in shares) at Dec. 31, 2021													68,153,336
Balance at Dec. 31, 2021													$ 68,153	124,915,560	(107,704,274)	(152,541)	(911,516)	16,215,382
Net loss																		(6,786,037)
Net loss																		(6,786,037)
Balance (in shares) at Sep. 30, 2022													68,907,394
Balance at Sep. 30, 2022													$ 68,907	126,666,340	(114,436,281)	(206,571)	(911,516)	11,180,879
Balance (in shares) at Mar. 31, 2022													68,153,336
Balance at Mar. 31, 2022													$ 68,153	125,385,315	(109,605,997)	(170,043)	(911,516)	14,765,912
Stock based compensation													$ 0	392,266	0	0	0	392,266
Common stock issued for services (in shares)													12,879
Common stock issued for services													$ 13	12,864				12,877
Common stock to be issued to employees for bonuses													147	(147)	0	0	0	0
Net loss													$ 0	0	(2,858,481)	(22,848)	0	(2,881,329)
Common stock to be issued for payment of consulting services (in shares)													246,028
Common stock to be issued for payment of consulting services													$ 246	345,689				345,935
Common stock issued to be employee for compensation	$ 225	$ (225)	$ 0	$ 0	$ 0	$ 0							27	39,973				40,000
Net loss													$ 0	0	(2,858,481)	(22,848)	0	(2,881,329)
Common stock issued to employee for compensation (in shares)	224,850												27,051
Common stock to be issued to employees for bonuses (in shares)													147,338
Balance (in shares) at Jun. 30, 2022													68,811,482
Balance at Jun. 30, 2022													$ 68,811	126,175,735	(112,464,478)	(192,891)	(911,516)	12,675,661
Stock based compensation														400,202				400,202
Net loss													$ 0	0	(1,971,803)	(13,680)	0	(1,985,483)
Common stock to be issued for payment of consulting services (in shares)													95,912
Common stock to be issued for payment of consulting services													$ 96	90,403	0	0	0	90,499
Net loss													$ 0	0	(1,971,803)	(13,680)	0	(1,985,483)
Balance (in shares) at Sep. 30, 2022													68,907,394
Balance at Sep. 30, 2022													$ 68,907	126,666,340	(114,436,281)	(206,571)	(911,516)	11,180,879
Balance (in shares) at Dec. 31, 2022													69,306,497
Balance at Dec. 31, 2022													$ 69,306	127,478,325	(116,410,405)	(219,276)	(911,516)	10,006,434
Stock based compensation														388,772	0	0		388,772
Common stock issued for services (in shares)	256,868						242,335
Common stock issued for services	$ 258	$ (258)				$ 0	$ 242	$ 125,758	$ 0	$ 0	$ 0	$ 126,000
Common stock to be issued to employees for bonuses														50,000				50,000
Net loss															(1,307,666)	(11,665)		(1,319,331)
Net loss															(1,307,666)	(11,665)		(1,319,331)
Balance (in shares) at Mar. 31, 2023													69,805,700
Balance at Mar. 31, 2023													$ 69,806	128,042,597	(117,718,071)	(230,941)	(911,516)	9,251,875
Balance (in shares) at Dec. 31, 2022													69,306,497
Balance at Dec. 31, 2022													$ 69,306	127,478,325	(116,410,405)	(219,276)	(911,516)	10,006,434
Net loss																		(5,024,264)
Net loss																		(5,024,264)
Balance (in shares) at Sep. 30, 2023													70,893,748
Balance at Sep. 30, 2023													$ 70,894	129,487,592	(121,400,682)	(253,263)	(911,516)	6,993,025
Balance (in shares) at Mar. 31, 2023													69,805,700
Balance at Mar. 31, 2023													$ 69,806	128,042,597	(117,718,071)	(230,941)	(911,516)	9,251,875
Stock based compensation														404,330				404,330
Common stock issued for services (in shares)													192,835
Common stock issued for services													$ 193	(193)	0	0	0	0
Common stock to be issued to employees for bonuses													$ 0	217,500	0	0	0	217,500
Net loss															(2,216,317)	(12,511)	0	(2,228,828)
Common stock to be issued for payment of consulting services (in shares)													109,204
Common stock to be issued for payment of consulting services													$ 109	56,677	0	0	0	56,786
Net loss															(2,216,317)	(12,511)	0	(2,228,828)
Balance (in shares) at Jun. 30, 2023													70,107,739
Balance at Jun. 30, 2023													$ 70,108	128,720,911	(119,934,388)	(243,452)	(911,516)	7,701,663
Stock based compensation														320,325	0	0	0	320,325
Common stock issued for services (in shares)													154,486
Common stock issued for services													$ 154	(154)	0	0	0	0
Net loss															(1,466,294)	(9,811)		(1,476,105)
Common stock to be issued for payment of consulting services (in shares)													631,523
Common stock to be issued for payment of consulting services													$ 632	396,510	0	0	0	397,142
Common stock issued to be employee for compensation														50,000	0	0	0	50,000
Net loss															(1,466,294)	(9,811)		(1,476,105)
Balance (in shares) at Sep. 30, 2023													70,893,748
Balance at Sep. 30, 2023													$ 70,894	$ 129,487,592	$ (121,400,682)	$ (253,263)	$ (911,516)	$ 6,993,025

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (5,024,264)	$ (6,786,037)
Depreciation expense	10,155	10,139
Amortization of intangibles	39,643	39,982
Stock based compensation	1,113,427	1,097,838
Inventory Reserve	109,159	430,245
Employees paid in stock	317,500	217,262
Expense paid in stock	579,928	436,434
Unrealized gain on marketable securities	6,208	0
Bad debt expense	16,076	100,000
Amortization of right-of-use asset	69,067	59,698
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	86,629	(248,457)
Increase in inventories	(799,454)	(440,574)
Increase in advances on contracts	(373,852)	(272,223)
Increase in prepaid expenses and other current assets	(134,881)	(102,858)
Increase in accounts payable	46,538	502,292
(Decrease) increase in accounts payable, related party	(166,855)	515,142
Decrease in accrued expenses	(13,098)	(367,074)
Increase (decrease) in accrued expenses, related party	103,287	(80,758)
Decrease operating right of use lease asset	(65,543)	(53,411)
Net cash used in operating activities	(4,080,330)	(4,942,360)
Cash flows from investing activities:
Purchase of furniture, fixtures, and equipment	(1,192)	(3,827)
Sale of Marketable securities	4,472,540	0
Purchase of Marketable securities	(6,929,218)	0
Net cash used in investing activities	(2,457,870)	(3,827)
Cash flows from financing activities:
Payments finance lease obligations	(6,486)	(6,486)
Net cash used in financing activities	(6,486)	(6,486)
Net decrease in cash and cash equivalents	(6,544,686)	(4,952,673)
Cash and cash equivalents at beginning of period	8,715,279	14,764,346
Cash and cash equivalents at end of period	$ 2,170,593	$ 9,811,673

Note 1 - Organization and Busin

Note 1 - Organization and Business	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 ORGANIZATION AND BUSINESS All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone Medical, Inc. (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent ; CompuFlo ; DPS Dynamic Pressure Sensing technology ; Milestone Scientific ; CathCheck the Milestone logo ; SafetyWand ; STA Single Tooth Anesthesia System ; and The Wand . Milestone Scientific was incorporated in the State of Delaware in August 1989. 160 Our device, using The Wand®, a single use disposable handpiece, is marketed in dentistry under the trademarks CompuDent STA Single Tooth Anesthesia System 41 510 CompuFlo

Note 2- Liquidity and Uncertain

Note 2- Liquidity and Uncertainties	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 LIQUIDITY AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one three nine September 30, 2023, 12 September 12, 2023 no one Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, and a reduction in operating expenses. However, the Company’s continued operations will depend on its ability to raise additional capital through various potential sources until it achieves profitability, if ever. In addition to its employees, the Company relies on (i) distributors, agents, and third third may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission (SEC) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation. 2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2022, 10 3. The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation, and cash flow assumptions regarding evaluations of going concern considerations. Actual results could differ from those estimates. 4. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no E-Commerce As of January 3, 2023, third Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not The Company terminated its major U.S. distributor contract as of December 31, 2022. March 31, 2023. December 31, 2022 September 30, 2023 Financing and Payment The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 third third two Disaggregation of Revenue The Company operates in two operating segments: dental and medical. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note 8 three nine September 30, 2023 2022. 5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three September 30, 2023 December 31, 2022, September 30, 2023, $250,000. 6. The Company’s marketable securities are comprised of treasury bills with original maturity greater than three 2016 01. The appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Declines in the fair values of equity securities that are considered other-than-temporary, are charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. As of September 30, 2023, 3 6 7. Accounts Receivable The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third 2 Distributors credit sales are due 90 September 30, 2023 December 31, 2022, 8. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first The valuation allowance creates a new cost basis for the inventory, and it is not 9. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, three September 30, 2023 2022, nine September 30, 2023 2022, nine September 30, 2023 2022, not nine September 30, 2023 2022, 10. Stock-Based Compensation Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718 11. Recent Accounting Pronouncements In June 2016, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” January 1, 2023, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” not In November 2019, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 dates 2016 13 2019 10, 2016 13 December 15, 2022, January 1, 2023, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 not

Note 4 - Inventories

Note 4 - Inventories	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 INVENTORIES Inventories consist of the following: September 30, 2023 December 31, 2022 Dental finished goods $ 2,090,638 $ 1,315,263 Medical finished goods, net 225,642 334,124 Component parts and other materials 166,350 142,948 Total inventories $ 2,482,630 $ 1,792,335 The Company has recorded an allowance on slow moving Medical finished goods due to the slow adoption of the epidural instruments and handpieces for approximately $1.0 million as of September 30, 2023 December 31, 2022.

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 5 ADVANCES ON CONTRACTS The advances on contracts represent funding of future STA devices, epidural instruments, and epidural replacements parts. The balance of the advances as of September 30, 2023 December 31, 2022

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 6 STOCKHOLDERS EQUITY Warrants The following table summarizes information about shares issuable under warrants outstanding as of September 30, 2023: Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2023 4,268,221 2.18 0.50 - Issued - - - - Exercised - - - - Expired or cancelled (3,953,649 ) - - - Outstanding and exercisable at September 30, 2023 314,572 0.50 0.35 132,120 S hares to Be Issued As of September 30, 2023 2022, As of September 30, 2023 2022, The following table summarizes information about shares to be issued on September 30, 2023 2022. September 30, 2023 September 30, 2022 Shares-to-be-issued, outstanding January 1, 2023 and 2022, respectively 2,440,673 2,066,343 Granted in current period 368,387 108,148 Issued in current period - (147,338 ) Shares-to be issued outstanding September 30, 2023 and 2022, respectively 2,809,060 2,027,153 Stock Options Plans The Milestone Scientific Inc. 2020 "2020 June 2031. may not three five Milestone Scientific recognizes compensation expense over the requisite service period. For three nine September 30, 2023, three nine September 30, 2022, A summary of option activity for employees under the plans and changes during the nine September 30, 2023 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 3,059,989 2.36 6.38 - Granted during 2023 - - - - Exercised during 2023 - - - - Forfeited or expired during 2023 (18,000 ) - - - Options outstanding September 30, 2023 3,041,989 2.29 5.66 - Exercisable, September 30, 2023 1,469,651 2.37 4.97 - A summary of option activity for non-employees under the plans and changes during the nine September 30, 2023 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 91,663 1.75 2.55 1,083 Granted during 2023 8,333 0.89 4.46 222 Expired during 2023 (8,333 ) 0.75 - - Options outstanding September 30, 2023 91,663 1.76 2.25 8,000 Exercisable, September 30, 2023 77,776 1.89 1.93 6,777 For the three nine September 30, 2023, three nine September 30, 2022, The information below summarizes the restricted stock award activity for the nine September 30, 2023. Number of Shares Weighted Average Grant-Date Fair Value per Award Non-vested as January 1, 2023 435,293 1.18 Granted 617,978 0.89 Vested (540,164 ) - Cancelled (30,676 ) - Non-vested as September 30, 2023 482,431 0.91 As of September 30, 2023, two three nine September 30, 2023, three nine September 30, 2022, not nine September 30, 2023, As of June 28, 2023, June 2023, first October 2023, January 2024, April 2024. three nine September 30, 2023, nine September 30, 2023,

Note 7 - Income Taxes

Note 7 - Income Taxes	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 7 INCOME TAXES The utilization of Milestone Scientific's net operating losses may 382 may

Note 8 - Segment and Geographic

Note 8 - Segment and Geographic Data	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 8 SEGMENT AND GEOGRAPHIC DATA We conduct our business through two not The following tables present information about our reportable and operating segments: For the Three Months ended September 30, For the Nine Months ended September 30, Sales Net Sales: 2023 2022 2023 2022 Dental $ 2,053,284 $ 2,206,499 $ 7,556,848 $ 6,509,619 Medical 6,000 9,200 10,000 55,350 Total net sales $ 2,059,284 $ 2,215,699 $ 7,566,848 $ 6,564,969 Operating Income (Loss): 2023 2022 2023 2022 Dental $ 458,474 $ 308,913 $ 1,699,349 $ 826,175 Medical (740,087 ) (937,468 ) (2,425,913 ) (3,788,842 ) Corporate (1,225,092 ) (1,384,940 ) (4,400,369 ) (3,850,189 ) Total operating loss $ (1,506,705 ) $ (2,013,495 ) $ (5,126,933 ) $ (6,812,856 ) Depreciation and Amortization: 2023 2022 2023 2022 Dental $ 1,051 $ 951 $ 3,439 $ 2,737 Medical 585 1,019 2,247 3,056 Corporate 14,260 14,691 44,112 44,328 Total depreciation and amortization $ 15,896 $ 16,661 $ 49,798 $ 50,121 Income (loss) before taxes and equity in earnings of affiliates: 2023 2022 2023 2022 Dental $ 458,504 $ 307,699 $ 1,698,790 $ 822,270 Medical (742,004 ) (938,963 ) (2,431,502 ) (3,793,236 ) Corporate (1,192,605 ) (1,354,219 ) (4,291,552 ) (3,815,071 ) Total loss before taxes and equity in earnings of affiliate $ (1,476,105 ) $ (1,985,483 ) $ (5,024,264 ) $ (6,786,037 ) Total Assets September 30, 2023 December 31, 2022 Dental $ 5,338,522 $ 3,875,978 Medical 498,113 620,373 Corporate 4,746,923 9,205,735 Total assets $ 10,583,558 $ 13,702,086 The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category: Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Domestic: US Dental Medical Grand Total Dental Medical Grand Total Instruments $ 230,615 $ - $ 230,615 $ 164,341 $ 7,500 $ 171,841 Handpieces 1,007,930 - 1,007,930 678,473 1,700 680,173 Accessories 14,822 - 14,822 24,304 - 24,304 Grand Total $ 1,253,367 $ - $ 1,253,367 $ 867,118 $ 9,200 $ 876,318 International: Rest of World Instruments $ 88,019 $ - $ 88,019 $ 436,069 $ - $ 436,069 Handpieces 700,697 6,000 706,697 881,616 - 881,616 Accessories 11,201 - 11,201 21,696 - 21,696 Grand Total $ 799,917 $ 6,000 $ 805,917 $ 1,339,381 $ - $ 1,339,381 Total Product Sales $ 2,053,284 $ 6,000 $ 2,059,284 $ 2,206,499 $ 9,200 $ 2,215,699 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Domestic: US Dental Medical Grand Total Dental Medical Grand Total Instruments $ 726,104 $ - $ 726,104 $ 442,336 $ 7,500 $ 449,836 Handpieces 3,277,830 - 3,277,830 2,275,865 25,750 2,301,615 Accessories 59,336 - 59,336 73,210 2,100 75,310 Grand Total $ 4,063,270 $ - $ 4,063,270 $ 2,791,411 $ 35,350 $ 2,826,761 International: Rest of World Instruments $ 961,224 $ - $ 961,224 $ 1,050,443 $ - $ 1,050,443 Handpieces 2,222,707 10,000 2,232,707 2,265,367 20,000 2,285,367 Accessories 39,647 - 39,647 42,434 - 42,434 Grand Total $ 3,223,578 $ 10,000 $ 3,233,578 $ 3,358,244 $ 20,000 $ 3,378,244 International: China Instruments $ 270,000 $ - $ 270,000 $ - $ - $ - Handpieces - - - 359,964 - 359,964 Accessories - - - - - - Grand Total $ 270,000 $ - $ 270,000 $ 359,964 $ - $ 359,964 Total Product Sales $ 7,556,848 $ 10,000 $ 7,566,848 $ 6,509,619 $ 55,350 $ 6,564,969

Note 9 - Concentrations

Note 9 - Concentrations	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 9 CONCENTRATIONS Milestone Scientific has informal arrangements with third September 30, 2023 December 31, 2022. On January 3, 2023, three September 30, 2023, one nine September 30, 2023, three September 30, 2022, two nine September 30, 2022, one We had four distributors that accounted for 41%, 24%, 13% and 10% of accounts receivable, respectively, for the nine September 30, 2023. two December 31, 2022. As of September 30, 2023 one December 31, 2022.

Note 10 - Related Party Transac

Note 10 - Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 10 -- RELATED PARTY TRANSACTIONS United Systems Milestone Scientific has a supply agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturer of our handpieces, pursuant to which manufacture is under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $636,000 and $1.9 million, respectively for the three nine September 30, 2023. three nine September 30, 2022. As of September 30, 2023 December 31, 2022, Other During 2022, three nine September 30, 2022, not 2023. Royalties payable to our Director of Clinical Affairs was approximately $104,000 and $370,000 for the three nine September 30, 2023, three nine September 30, 2022, three nine September 30, 2023 2022, As of September 30, 2023 December 31, 2022, Pursuant to a Succession Agreement dated April 6, 2021 July 10, 2017 July 10, 2017 ( 9.5 May 19, 2021. three nine September 30, 2023 2022, three nine September 30, 2023 2022,

Note 11 - Commitments

Note 11 - Commitments	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS ( 1 Contract Manufacturing Agreement Milestone Scientific has informal arrangements with third September 30, 2023. September 30, 2023, December 31, 2022, September 30, 2023 December 31, 2022 ( 2 Leases Operating Leases The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company’s leases do not ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include non-cancellable lease periods. Renewal option periods are not not The components of lease expense were as follows: Three months ended Nine months ended September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Cash paid for operating lease liabilities $ 34,320 $ 31,999 $ 98,083 $ 95,996 Cash paid for finance lease liabilities 2,685 2,685 8,055 8,055 Right-of-use assets obtained in exchange for new operating lease liabilities (1) 663,009 Property and equipment obtained in exchange for new finance lease liabilities 43,242 Weighted Average Remaining Lease Term Finance leases (years) 1.3 Operating leases (years) 3.5 Weighted-average discount rate – operating leases 9.20 % Weighted-average discount rate – finance leases 9.20 %

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission (SEC) and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in the consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2022, 10
Use of Estimates, Policy [Policy Text Block]	3. The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the inventory valuation, and cash flow assumptions regarding evaluations of going concern considerations. Actual results could differ from those estimates.
Revenue [Policy Text Block]	4. Revenue Recognition The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition, the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products directly to consumers in the United States and through a global distribution network that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. The Company has no E-Commerce As of January 3, 2023, third Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers’ return rights and the Company’s historical experience with returns and the amount of product in the distribution channel not The Company terminated its major U.S. distributor contract as of December 31, 2022. March 31, 2023. December 31, 2022 September 30, 2023 Financing and Payment The Company's payment terms differ by geography and customer, but payments from distributors are required within 90 third third two Disaggregation of Revenue The Company operates in two operating segments: dental and medical. Therefore, results of the Company's operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. See Note 8 three nine September 30, 2023 2022.
Cash and Cash Equivalents, Policy [Policy Text Block]	5. Cash and Cash Equivalents Milestone Scientific considers all highly liquid investments purchased with an original maturity of three September 30, 2023 December 31, 2022, September 30, 2023, $250,000.
Marketable Securities, Policy [Policy Text Block]	6. The Company’s marketable securities are comprised of treasury bills with original maturity greater than three 2016 01. The appropriate classification of marketable securities is determined at the time of purchase and evaluated as of each reporting balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair value is determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Declines in the fair values of equity securities that are considered other-than-temporary, are charged to other income (expense), net. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost. As of September 30, 2023, 3 6
Accounts Receivable [Policy Text Block]	7. Accounts Receivable The E-commerce portal sells directly to end users and accepts online payments via credit and debit cards via a third 2 Distributors credit sales are due 90 September 30, 2023 December 31, 2022,
Inventory, Policy [Policy Text Block]	8. Inventories Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first The valuation allowance creates a new cost basis for the inventory, and it is not
Earnings Per Share, Policy [Policy Text Block]	9. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, three September 30, 2023 2022, nine September 30, 2023 2022, nine September 30, 2023 2022, not nine September 30, 2023 2022,
Share-Based Payment Arrangement [Policy Text Block]	10. Stock-Based Compensation Milestone Scientific accounts for stock-based compensation under ASC Topic 718, 718
New Accounting Pronouncements, Policy [Policy Text Block]	11. Recent Accounting Pronouncements In June 2016, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” January 1, 2023, 2016 13, Measurement of Credit Losses on Financial Instruments 2016 13” not In November 2019, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 dates 2016 13 2019 10, 2016 13 December 15, 2022, January 1, 2023, 2019 10, Financial Instruments - Credit Losses (Topic, 326 815 842 not

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2023 December 31, 2022 Dental finished goods $ 2,090,638 $ 1,315,263 Medical finished goods, net 225,642 334,124 Component parts and other materials 166,350 142,948 Total inventories $ 2,482,630 $ 1,792,335

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2023 4,268,221 2.18 0.50 - Issued - - - - Exercised - - - - Expired or cancelled (3,953,649 ) - - - Outstanding and exercisable at September 30, 2023 314,572 0.50 0.35 132,120
Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	September 30, 2023 September 30, 2022 Shares-to-be-issued, outstanding January 1, 2023 and 2022, respectively 2,440,673 2,066,343 Granted in current period 368,387 108,148 Issued in current period - (147,338 ) Shares-to be issued outstanding September 30, 2023 and 2022, respectively 2,809,060 2,027,153
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 3,059,989 2.36 6.38 - Granted during 2023 - - - - Exercised during 2023 - - - - Forfeited or expired during 2023 (18,000 ) - - - Options outstanding September 30, 2023 3,041,989 2.29 5.66 - Exercisable, September 30, 2023 1,469,651 2.37 4.97 - Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2023 91,663 1.75 2.55 1,083 Granted during 2023 8,333 0.89 4.46 222 Expired during 2023 (8,333 ) 0.75 - - Options outstanding September 30, 2023 91,663 1.76 2.25 8,000 Exercisable, September 30, 2023 77,776 1.89 1.93 6,777
Restricted Stock [Member]
Notes Tables
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]	Number of Shares Weighted Average Grant-Date Fair Value per Award Non-vested as January 1, 2023 435,293 1.18 Granted 617,978 0.89 Vested (540,164 ) - Cancelled (30,676 ) - Non-vested as September 30, 2023 482,431 0.91

Note 8 - Segment and Geograph_2

Note 8 - Segment and Geographic Data (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	For the Three Months ended September 30, For the Nine Months ended September 30, Sales Net Sales: 2023 2022 2023 2022 Dental $ 2,053,284 $ 2,206,499 $ 7,556,848 $ 6,509,619 Medical 6,000 9,200 10,000 55,350 Total net sales $ 2,059,284 $ 2,215,699 $ 7,566,848 $ 6,564,969 Operating Income (Loss): 2023 2022 2023 2022 Dental $ 458,474 $ 308,913 $ 1,699,349 $ 826,175 Medical (740,087 ) (937,468 ) (2,425,913 ) (3,788,842 ) Corporate (1,225,092 ) (1,384,940 ) (4,400,369 ) (3,850,189 ) Total operating loss $ (1,506,705 ) $ (2,013,495 ) $ (5,126,933 ) $ (6,812,856 ) Depreciation and Amortization: 2023 2022 2023 2022 Dental $ 1,051 $ 951 $ 3,439 $ 2,737 Medical 585 1,019 2,247 3,056 Corporate 14,260 14,691 44,112 44,328 Total depreciation and amortization $ 15,896 $ 16,661 $ 49,798 $ 50,121 Income (loss) before taxes and equity in earnings of affiliates: 2023 2022 2023 2022 Dental $ 458,504 $ 307,699 $ 1,698,790 $ 822,270 Medical (742,004 ) (938,963 ) (2,431,502 ) (3,793,236 ) Corporate (1,192,605 ) (1,354,219 ) (4,291,552 ) (3,815,071 ) Total loss before taxes and equity in earnings of affiliate $ (1,476,105 ) $ (1,985,483 ) $ (5,024,264 ) $ (6,786,037 ) Total Assets September 30, 2023 December 31, 2022 Dental $ 5,338,522 $ 3,875,978 Medical 498,113 620,373 Corporate 4,746,923 9,205,735 Total assets $ 10,583,558 $ 13,702,086
Sales by Product and by Geographical Region [Table Text Block]	Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Domestic: US Dental Medical Grand Total Dental Medical Grand Total Instruments $ 230,615 $ - $ 230,615 $ 164,341 $ 7,500 $ 171,841 Handpieces 1,007,930 - 1,007,930 678,473 1,700 680,173 Accessories 14,822 - 14,822 24,304 - 24,304 Grand Total $ 1,253,367 $ - $ 1,253,367 $ 867,118 $ 9,200 $ 876,318 International: Rest of World Instruments $ 88,019 $ - $ 88,019 $ 436,069 $ - $ 436,069 Handpieces 700,697 6,000 706,697 881,616 - 881,616 Accessories 11,201 - 11,201 21,696 - 21,696 Grand Total $ 799,917 $ 6,000 $ 805,917 $ 1,339,381 $ - $ 1,339,381 Total Product Sales $ 2,053,284 $ 6,000 $ 2,059,284 $ 2,206,499 $ 9,200 $ 2,215,699 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Domestic: US Dental Medical Grand Total Dental Medical Grand Total Instruments $ 726,104 $ - $ 726,104 $ 442,336 $ 7,500 $ 449,836 Handpieces 3,277,830 - 3,277,830 2,275,865 25,750 2,301,615 Accessories 59,336 - 59,336 73,210 2,100 75,310 Grand Total $ 4,063,270 $ - $ 4,063,270 $ 2,791,411 $ 35,350 $ 2,826,761 International: Rest of World Instruments $ 961,224 $ - $ 961,224 $ 1,050,443 $ - $ 1,050,443 Handpieces 2,222,707 10,000 2,232,707 2,265,367 20,000 2,285,367 Accessories 39,647 - 39,647 42,434 - 42,434 Grand Total $ 3,223,578 $ 10,000 $ 3,233,578 $ 3,358,244 $ 20,000 $ 3,378,244 International: China Instruments $ 270,000 $ - $ 270,000 $ - $ - $ - Handpieces - - - 359,964 - 359,964 Accessories - - - - - - Grand Total $ 270,000 $ - $ 270,000 $ 359,964 $ - $ 359,964 Total Product Sales $ 7,556,848 $ 10,000 $ 7,566,848 $ 6,509,619 $ 55,350 $ 6,564,969

Note 11 - Commitments (Tables)

Note 11 - Commitments (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Lease, Cost and Other Information [Table Text Block]	Three months ended Nine months ended September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Cash paid for operating lease liabilities $ 34,320 $ 31,999 $ 98,083 $ 95,996 Cash paid for finance lease liabilities 2,685 2,685 8,055 8,055 Right-of-use assets obtained in exchange for new operating lease liabilities (1) 663,009 Property and equipment obtained in exchange for new finance lease liabilities 43,242 Weighted Average Remaining Lease Term Finance leases (years) 1.3 Operating leases (years) 3.5 Weighted-average discount rate – operating leases 9.20 % Weighted-average discount rate – finance leases 9.20 %

Note 2- Liquidity and Uncerta_2

Note 2- Liquidity and Uncertainties (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Retained Earnings (Accumulated Deficit)	$ (121,400,682)		$ (121,400,682)		$ (116,410,405)
Operating Income (Loss)	$ (1,506,705)	$ (2,013,495)	$ (5,126,933)	$ (6,812,856)

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 shares	Dec. 31, 2022 USD ($)
Allowance for Sales Returns			$ 0		$ 179,000
Number of Operating Segments			2
Cash, Uninsured Amount	$ 1,700,000		$ 1,700,000
Marketable Securities, Current	2,450,470		2,450,470		0
Accounts Receivable, Allowance for Credit Loss	$ 26,000		$ 26,000		10,000
Weighted Average Number of Shares Outstanding, Basic (in shares) | shares	73,730,921	70,975,420	72,374,693	70,480,706
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares			3,930,654	8,135,704
US Treasury Securities [Member]
Marketable Securities, Current	$ 2,400,000		$ 2,400,000
Money Market Funds [Member]
Cash Equivalents, at Carrying Value	$ 2,200,000		$ 2,200,000		$ 8,700,000

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Inventory Write-down	$ 90,000
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves	$ 1,000,000	$ 1,000,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Component parts and other materials	$ 166,350	$ 142,948
Total inventories	2,482,630	1,792,335
Dental Segment [Member]
Finished goods, net	2,090,638	1,315,263
Medical Segment [Member]
Finished goods, net	$ 225,642	$ 334,124

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts (Details Textual) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Advances on Inventory Purchases	$ 1,699,153	$ 1,325,301

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity (Details Textual) - USD ($)		3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 28, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		2,809,060	2,027,153		2,809,060	2,027,153	2,440,673	2,066,343
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Payment Arrangement, Expense		$ 3,800	$ 5,000		$ 17,000	$ 15,000
Share-Based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense		321,000	$ 233,000		$ 1,100,000	$ 1,100,000
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 0.89
Restricted Stock [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense		$ 137,500			$ 445,000
The 2020 Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)					11,500,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
The 2020 Equity Incentive Plan [Member] | Vice Chairman of the Board of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					5 years
Chief Executive Officer, and Other Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		2,426,364	1,852,789		2,426,364	1,852,789
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		382,696	174,364		382,696	174,364
Territory Manager [Member] | Restricted Stock [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)		18,947			18,947
Share-Based Payment Arrangement, Expense		$ 36,500	$ 10,400		$ 17,700	$ 37,500
Deferred Compensation Arrangement with Individual, Requisite Service Period (Year)					2 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		5,200			$ 5,200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					5 months 15 days
Board of Directors [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	617,978
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 0.89
Director [Member] | Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 269,000			$ 269,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					6 months
Director [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage				25%
Director [Member] | Restricted Stock [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage				25%

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Warrants (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Outstanding (in shares)	4,268,221
Outstanding (in dollars per share)	$ 2.18
Outstanding (Year)	4 months 6 days	6 months
Issued, number of shares (in shares)	0
Issued, weighted average exercise price (in dollars per share)	$ 0
Exercised, number of shares (in shares)	0
Exercised, weighted average exercise price (in dollars per share)	$ 0
Expired or cancelled, number of shares (in shares)	(3,953,649)
Expired or cancelled, weighted average exercise price (in dollars per share)	$ 0
Outstanding (in shares)	314,572	4,268,221
Outstanding (in dollars per share)	$ 0.5	$ 2.18
Outstanding	$ 132,120

Note 6 - Stockholders' Equity_3

Note 6 - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Shares-to-be-issued, outstanding (in shares)	2,440,673	2,066,343
Granted in current period (in shares)	368,387	108,148
Issued in current period (in shares)	0	(147,338)
Shares-to be issued outstanding September 30, 2023 and 2022, respectively (in shares)	2,809,060	2,027,153

Note 6 - Stockholders' Equity_4

Note 6 - Stockholders' Equity - Summary of Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Aggregate intrinsic value, outstanding		$ 1,083
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]
Options outstanding, balance (in shares)	3,059,989
Weighted average exercise price, outstanding (in dollars per share)	$ 2.36
Weighted average remaining contractual life, outstanding (Year)	5 years 7 months 28 days	6 years 4 months 17 days
Granted, options (in shares)	0
Weighted average exercise price, granted (in dollars per share)	$ 0
Exercised, options (in shares)	0
Weighted average exercise price, exercised (in dollars per share)	$ 0
Forfeited and expired, options (in shares)	(18,000)
Weighted average exercise price, forfeited or expired (in dollars per share)	$ 0
Options outstanding, balance (in shares)	3,041,989	3,059,989
Weighted average exercise price, outstanding (in dollars per share)	$ 2.29	$ 2.36
Exercisable, options (in shares)	1,469,651
Weighted average exercise price, exercisable (in dollars per share)	$ 2.37
Weighted average remaining contractual life, exercisable (Year)	4 years 11 months 19 days
Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Options outstanding, balance (in shares)	91,663
Weighted average exercise price, outstanding (in dollars per share)	$ 1.75
Weighted average remaining contractual life, outstanding (Year)	2 years 3 months	2 years 6 months 18 days
Granted, options (in shares)	8,333
Weighted average exercise price, granted (in dollars per share)	$ 0.89
Forfeited and expired, options (in shares)	(8,333)
Weighted average exercise price, forfeited or expired (in dollars per share)	$ 0.75
Options outstanding, balance (in shares)	91,663	91,663
Weighted average exercise price, outstanding (in dollars per share)	$ 1.76	$ 1.75
Exercisable, options (in shares)	77,776
Weighted average exercise price, exercisable (in dollars per share)	$ 1.89
Weighted average remaining contractual life, exercisable (Year)	1 year 11 months 4 days
Aggregate intrinsic value, outstanding	$ 8,000
Weighted average remaining contractual life, granted (Year)	4 years 5 months 15 days
Aggregate intrinsic value, exercisable	$ 6,777

Note 6 - Stockholders' Equity_5

Note 6 - Stockholders' Equity - Schedule of Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Non-vested as January 1, 2023 (in shares)	435,293
Non-vested as January 1, 2023 (in dollars per share) | $ / shares	$ 1.18
Granted, Shares (in shares)	617,978
Granted, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares	$ 0.89
Vested, Shares (in shares)	(540,164)
Vested, Weighted Average Grant-Date Fair Value per Award (in dollars per share) | $ / shares	$ 0
Cancelled, Shares (in shares)	(30,676)
Non-vested as September 30, 2023 (in shares)	482,431
Non-vested as September 30, 2023 (in dollars per share) | $ / shares	$ 0.91

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual)	9 Months Ended
	Sep. 30, 2023
Percentage of Valuation Allowance	100%

Note 8 - Segment and Geograph_3

Note 8 - Segment and Geographic Data (Details Textual)	9 Months Ended
	Sep. 30, 2023
Number of Reportable Segments	2

Note 8 - Segment and Geograph_4

Note 8 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Product sales, net	$ 2,059,284	$ 2,215,699	$ 7,566,848	$ 6,564,969
Operating Income (Loss)	(1,506,705)	(2,013,495)	(5,126,933)	(6,812,856)
Depreciation and Amortization	15,896	16,661	49,798	50,121
Income (loss) before taxes and equity in earnings of affiliates:	(1,476,105)	(1,985,483)	(5,024,264)	(6,786,037)
Total assets	10,583,558		10,583,558		$ 13,702,086
Dental Segment [Member]
Product sales, net	2,053,284	2,206,499	7,556,848	6,509,619
Medical Segment [Member]
Product sales, net	6,000	9,200	10,000	55,350
Operating Segments [Member] | Dental Segment [Member]
Product sales, net	2,053,284	2,206,499	7,556,848	6,509,619
Operating Income (Loss)	458,474	308,913	1,699,349	826,175
Depreciation and Amortization	1,051	951	3,439	2,737
Income (loss) before taxes and equity in earnings of affiliates:	458,504	307,699	1,698,790	822,270
Total assets	5,338,522		5,338,522		3,875,978
Operating Segments [Member] | Medical Segment [Member]
Product sales, net	6,000	9,200	10,000	55,350
Operating Income (Loss)	(740,087)	(937,468)	(2,425,913)	(3,788,842)
Depreciation and Amortization	585	1,019	2,247	3,056
Income (loss) before taxes and equity in earnings of affiliates:	(742,004)	(938,963)	(2,431,502)	(3,793,236)
Total assets	498,113		498,113		620,373
Corporate, Non-Segment [Member]
Operating Income (Loss)	(1,225,092)	(1,384,940)	(4,400,369)	(3,850,189)
Depreciation and Amortization	14,260	14,691	44,112	44,328
Income (loss) before taxes and equity in earnings of affiliates:	(1,192,605)	$ (1,354,219)	(4,291,552)	$ (3,815,071)
Total assets	$ 4,746,923		$ 4,746,923		$ 9,205,735

Note 8 - Segment and Geograph_5

Note 8 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Product sales, net	$ 2,059,284	$ 2,215,699	$ 7,566,848	$ 6,564,969
Dental Segment [Member]
Product sales, net	2,053,284	2,206,499	7,556,848	6,509,619
Medical Segment [Member]
Product sales, net	6,000	9,200	10,000	55,350
Domestic [Member]
Product sales, net	1,253,367	876,318	4,063,270	2,826,761
Domestic [Member] | Instruments [Member]
Product sales, net	230,615	171,841	726,104	449,836
Domestic [Member] | Handpieces [Member]
Product sales, net	1,007,930	680,173	3,277,830	2,301,615
Domestic [Member] | Accessories [Member]
Product sales, net	14,822	24,304	59,336	75,310
Domestic [Member] | Dental Segment [Member]
Product sales, net	1,253,367	867,118	4,063,270	2,791,411
Domestic [Member] | Dental Segment [Member] | Instruments [Member]
Product sales, net	230,615	164,341	726,104	442,336
Domestic [Member] | Dental Segment [Member] | Handpieces [Member]
Product sales, net	1,007,930	678,473	3,277,830	2,275,865
Domestic [Member] | Dental Segment [Member] | Accessories [Member]
Product sales, net	14,822	24,304	59,336	73,210
Domestic [Member] | Medical Segment [Member]
Product sales, net	0	9,200	0	35,350
Domestic [Member] | Medical Segment [Member] | Instruments [Member]
Product sales, net	0	7,500	0	7,500
Domestic [Member] | Medical Segment [Member] | Handpieces [Member]
Product sales, net	0	1,700	0	25,750
Domestic [Member] | Medical Segment [Member] | Accessories [Member]
Product sales, net	0	0	0	2,100
Rest of World [Member]
Product sales, net	805,917	1,339,381	3,233,578	3,378,244
Rest of World [Member] | Instruments [Member]
Product sales, net	88,019	436,069	961,224	1,050,443
Rest of World [Member] | Handpieces [Member]
Product sales, net	706,697	881,616	2,232,707	2,285,367
Rest of World [Member] | Accessories [Member]
Product sales, net	11,201	21,696	39,647	42,434
Rest of World [Member] | Dental Segment [Member]
Product sales, net	799,917	1,339,381	3,223,578	3,358,244
Rest of World [Member] | Dental Segment [Member] | Instruments [Member]
Product sales, net	88,019	436,069	961,224	1,050,443
Rest of World [Member] | Dental Segment [Member] | Handpieces [Member]
Product sales, net	700,697	881,616	2,222,707	2,265,367
Rest of World [Member] | Dental Segment [Member] | Accessories [Member]
Product sales, net	11,201	21,696	39,647	42,434
Rest of World [Member] | Medical Segment [Member]
Product sales, net	6,000	0	10,000	20,000
Rest of World [Member] | Medical Segment [Member] | Instruments [Member]
Product sales, net	0	0	0	0
Rest of World [Member] | Medical Segment [Member] | Handpieces [Member]
Product sales, net	6,000	0	10,000	20,000
Rest of World [Member] | Medical Segment [Member] | Accessories [Member]
Product sales, net	$ 0	$ 0	0	0
CHINA
Product sales, net			270,000	359,964
CHINA | Instruments [Member]
Product sales, net			270,000	0
CHINA | Handpieces [Member]
Product sales, net			0	359,964
CHINA | Accessories [Member]
Product sales, net			0	0
CHINA | Dental Segment [Member]
Product sales, net			270,000	359,964
CHINA | Dental Segment [Member] | Instruments [Member]
Product sales, net			270,000	0
CHINA | Dental Segment [Member] | Handpieces [Member]
Product sales, net			0	359,964
CHINA | Dental Segment [Member] | Accessories [Member]
Product sales, net			0	0
CHINA | Medical Segment [Member]
Product sales, net			0	0
CHINA | Medical Segment [Member] | Instruments [Member]
Product sales, net			0	0
CHINA | Medical Segment [Member] | Handpieces [Member]
Product sales, net			0	0
CHINA | Medical Segment [Member] | Accessories [Member]
Product sales, net			$ 0	$ 0

Note 9 - Concentrations (Detail

Note 9 - Concentrations (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2023
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Distributors	1		1
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | E-Commerce [Member]
Concentration Risk, Percentage	60%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor One [Member]
Concentration Risk, Percentage	13%	11%	46%	36%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Distributor Two [Member]
Concentration Risk, Percentage		32%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Distributors	4		4		2
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor One [Member]
Concentration Risk, Percentage			41%		33%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Two [Member]
Concentration Risk, Percentage			24%		20%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Three [Member]
Concentration Risk, Percentage			13%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Distributor Four [Member]
Concentration Risk, Percentage			10%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Related Party [Member]
Number of Vendors	2		2			1
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor One [Member] | Related Party [Member]
Concentration Risk, Percentage			35%		42%
Accounts Payable [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member] | Related Party [Member]
Concentration Risk, Percentage			19%

Note 10 - Related Party Trans_2

Note 10 - Related Party Transactions (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 10, 2017	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Previous President and Chief Executive Officer [Member]
Increase (Decrease) in Deferred Compensation	$ (100,000)
Employment Agreement, Base Compensation	200,000
Consultant [Member]
Increase (Decrease) in Deferred Compensation	(100,000)
Employment Agreement, Base Compensation	$ 200,000
Director of Clinical Affairs [Member]
Accounts Payable and Accrued Liabilities, Current			$ 104,000		$ 104,000	$ 120,000
Royalty Expense		$ 104,000	108,000	$ 370,000	322,000
Professional Fees		39,000	39,000	117,000	117,000
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party		636,000	658,000	1,900,000	2,300,000
Manufacturing Agreement for Handpieces [Member] | Related Party [Member]
Accounts Payable and Accrued Liabilities, Current		630,000		630,000		$ 819,000
Consulting Services [Member]
Costs and Expenses, Related Party			25,000		75,000
Managing Director, China Operations [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense		50,000	50,000	150,000	150,000
Consultant [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense		$ 50,000	$ 50,000	$ 150,000	$ 150,000

Note 11 - Commitments (Details

Note 11 - Commitments (Details Textual)	9 Months Ended
	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Advances on Inventory Purchases	$ 1,699,153	$ 1,325,301
Purchase Commitment for Devices [Member]
Purchase Commitment Number Of Units	2,800
Purchase Commitment, Remaining Minimum Amount Committed	$ 2,700,000	1,700,000
Advances on Inventory Purchases	1,700,000	1,200,000
Purchase Commitment For Devices Beginning In 2021 [Member]
Advances on Inventory Purchases	$ 41,000	$ 41,000

Note 11 - Commitments - Lease E

Note 11 - Commitments - Lease Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash paid for operating lease liabilities	$ 34,320	$ 31,999	$ 98,083	$ 95,996
Cash paid for finance lease liabilities	$ 2,685	$ 2,685	$ 8,055	8,055
Right-of-use assets obtained in exchange for new operating lease liabilities (1)				663,009
Property and equipment obtained in exchange for new finance lease liabilities				$ 43,242
Finance leases (years) (Year)		1 year 3 months 18 days		1 year 3 months 18 days
Operating leases (years) (Year)		3 years 6 months		3 years 6 months
Weighted-average discount rate – operating leases	9.20%		9.20%
Weighted-average discount rate – finance leases	9.20%		9.20%